Analyst Reco. BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
153.1 ^USD	+0.26%		-8.53%	-15.11%

May. 28	BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	MT
May. 28	BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating	Mar. 27	MT
Nomura Adjusts Beigene’s Price Target to HK$150.60 From HK$162.05, Keeps at Buy	Feb. 22	MT
Nomura Adjusts BeiGene Price Target to $268.36 From $253.14, Maintains Buy Rating	Nov. 07	MT
Citigroup Lowers Price Target on BeiGene to $285 From $290, Maintains Buy Rating	23-10-26	MT
Future Rate Hike Fears Bring Hong Kong Stocks to Slump; BeiGene Slips 7%	23-09-21	MT
Citigroup Raises BeiGene Price Target to $290 From $285, Maintains Buy Rating	23-09-20	MT
Macquarie Starts BeiGene at Outperform, $259 Price Target	23-09-12	MT
Morgan Stanley Adjusts BeiGene's Price Target to $319 From $321, Keeps Overweight Rating	23-08-29	MT
Jefferies Starts BeiGene at Buy With $287 Price Target	23-08-17	MT
JPMorgan Chase Adjusts Price Target on BeiGene to $300 From $297, Maintains Overweight Rating	23-08-07	MT
Nomura Adjusts BeiGene Price Target to $253.14 From $309.47, Maintains Buy Rating	23-07-20	MT
Nomura Adjusts BeiGene's Price Target to HK$152.86 From HK$186.87, Keeps at Buy	23-07-20	MT
Citigroup Initiates BeiGene With Buy Rating, $275 Price Target	23-07-17	MT
Bernstein Downgrades BeiGene to Market Perform From Outperform, Cuts Price Target to $196 From $335	23-06-30	MT
Nomura Adjusts BeiGene's Price Target to HK$186.87 From HK$172.81, Keeps at Buy	23-05-05	MT
Nomura Adjusts BeiGene Price Target to $309.47 From $286.19, Maintains Buy Rating	23-05-05	MT
Morgan Stanley Adjusts Price Target on BeiGene to $321 From $325, Maintains Overweight Rating	23-02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. BeiGene, Ltd.

Equities

BGNE

US07725L1026

Analyst Reco.

Filters